1 Combining a prioritization strategy and functional studies nominates 5'UTR

variants underlying inherited retinal disease

- 3 Alfredo Dueñas Rey^{1,2}, Marta del Pozo Valero^{1,2,3,*}, Manon Bouckaert^{1,2*}, Filip Van Den Broeck^{4,5},
- 4 Malena Daich Varela^{6,7}, Mattias Van Heetvelde^{1,2}, Marieke De Bruyne^{1,2}, Stijn Van de Sompele^{1,2},
- 5 Miriam Bauwens^{1,2}, Jamie Ellingford^{8,9,10}, Hanne Lenaerts^{1,2}, Quinten Mahieu^{1,2}, Dragana Josifova¹¹,
- 6 Genomics England Research Consortium¹⁰, Carlo Rivolta^{12,13,14}, Andrew Webster^{6,7}, Gavin Arno^{6,7},
- 7 Carmen Ayuso^{3,15}, Julie De Zaeytijd^{4,5}, Bart P. Leroy^{1,4,5,16}, Elfride De Baere^{1,2}, Frauke Coppieters^{1,2,17}
- 8 1. Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.
- 9 2. Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
- 10 3. Department of Genetics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, University
- 11 Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM).
- 12 4. Department of Ophthalmology, Ghent University Hospital, Ghent, Belgium.
- 13 5. Department of Head & Skin, Ghent University, Ghent, Belgium.
- 14 6. UCL Institute of Ophthalmology, London, UK.
- 15 7. Moorfields Eye Hospital, London, UK.
- 8. Division of Evolution, Infection and Genomic Sciences, School of Biological Sciences, Faculty of
- 17 Biology, Medicines and Health, University of Manchester, Manchester, UK.
- 18 9. Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS
- 19 Foundation Trust, Manchester, UK.
- 20 10. Genomics England, London, UK.
- 21 11. Clinical Genetics Department, Guy's Hospital, London, UK.
- NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 12. Department of Ophthalmology, University of Basel, Switzerland.

23	13. Institute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland.
24	14. Department of Genetics and Genome Biology, University of Leicester, Leicester, UK.
25	15. Center for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III,
26	Madrid, Spain.
27	16. Division of Ophthalmology & Center for Cellular & Molecular Therapeutics, Children's Hospital of
28	Philadelphia, Philadelphia, PA, USA.
29	17. Department of Pharmaceutics, Ghent University, Ghent, Belgium.
30	
31	* Shared second co-authors
32	Corresponding author: Frauke Coppieters (frauke.coppieters@ugent.be)
33	
34	
25	
35	
36	
37	
38	
30	
39	
40	
41	

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

Abstract **Background** | 5' untranslated regions (5'UTRs) are essential modulators of protein translation. Predicting the impact of 5'UTR variants is challenging and typically not performed in routine diagnostics. Here, we present a combined approach of a comprehensive prioritization strategy and subsequent functional assays to evaluate 5'UTR variation in two large cohorts of patients with inherited retinal diseases (IRDs). Methods | We performed an isoform-level re-analysis of retinal RNA-seq data to identify the protein-coding transcripts of 378 IRD genes with highest expression in retina. We evaluated the coverage of these 5'UTRs by different whole exome sequencing (WES) capture kits. The selected 5'UTRs were analyzed in whole genome sequencing (WGS) and WES data from IRD sub-cohorts from the 100,000 Genomes Project (n = 2,417 WGS) and an in-house database (n = 1,682 WES), respectively. Identified variants were annotated for 5'UTR-relevant features and classified into 7 distinct categories based on their predicted functional consequence. We developed a variant prioritization strategy by integrating population frequency, specific criteria for each category, and family and phenotypic data. A selection of candidate variants underwent functional validation using diverse experimental approaches. Results | Isoform-level re-quantification of retinal gene expression revealed 76 IRD genes with a non-canonical retina-enriched isoform, of which 20 display a fully distinct 5'UTR compared to that of their canonical isoform. Depending on the probe-design 3-20% of IRD genes have 5'UTRs fully captured by WES. After analyzing these regions in both IRD cohorts we prioritized 11 (likely) pathogenic variants in 10 genes (ARL3, MERTK, NDP, NMNAT1, NPHP4, PAX6, PRPF31, PRPF4, RDH12, RD3), of which 8 were novel. Functional analyses further supported the pathogenicity of 2 variants. The MERTK:c.-125G>A variant, overlapping a transcriptional

start site, was shown to significantly reduce both luciferase mRNA levels and activity. The RDH12:c.-123C>T variant was found in cis with the reported hypomorphic RDH12:c.701G>A (p.Arg234His) variant in 11 patients. This 5'UTR variant, predicted to introduce an upstream open reading frame, was shown to result in reduced RDH12 protein but unaltered mRNA levels. **Conclusions** | This study demonstrates the importance of 5'UTR variants implicated in IRDs and provides a systematic approach for 5'UTR annotation and validation that is applicable to other inherited diseases. **Keywords** 5'untranslated region (5'UTR), upstream open reading frame (uORF), non-coding variation, whole genome sequencing (WGS), whole exome sequencing (WES), in silico prioritization, variant interpretation, functional studies, inherited retinal disease (IRD).

Background

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

Among the numerous non-coding regulatory regions found across the human genome, 5' untranslated regions (5'UTRs) are major determinants of post-transcriptional control and translation efficiency^{1,2}. These regions, with an average length of about 200 nucleotides in humans, are located immediately upstream from protein-coding sequences and include the Kozak consensus sequence around the AUG start codon³. 5'UTRs harbor numerous cisregulatory elements such as internal ribosomal entry sites (IRES) and upstream open reading frames (uORFs), which can recruit scanning ribosomes and initiate translation⁴. In particular, uORFs, defined by an upstream start codon in-frame with a stop codon preceding the end of the primary open reading frame, can decrease downstream protein expression up to 80%⁵. Furthermore, 5'UTRs can serve as platforms for the formation of secondary and tertiary mRNA structures like stem-loops, hairpins, and RNA G-quadruplexes which further influence mRNA translation^{6,7}. Given the critical importance of 5'UTRs as modulators of protein expression, genetic variation within these regions can contribute to disease pathogenesis, as shown by several examples in a wide range of inherited diseases^{8–11}. With the expanding implementation of massively parallel sequencing technologies in clinical practice, the rare disease field has witnessed a true paradigm shift enabling improved molecular diagnosis for many affected individuals 12-15. Despite these advancements, and although this varies greatly across individuals with diverse clinical indications, a significant fraction of cases with suspected Mendelian disorders remains unsolved 12,13,16-18. To date, 5'UTR variants are often not evaluated because of the multiple challenges they entail. Firstly, detection relies on inclusion of these non-coding regions in targeted resequencing panels or whole genome sequencing, which has been limited to date¹⁹. Secondly, interpretation of the effect is more difficult due to different mechanisms⁸ and our relative lack

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

of understanding of the functional consequences of 5'UTR variants. Finally, functional evidence is necessary to support their pathogenicity and hence confirm the molecular diagnosis. Recently, to close the annotation and interpretation gap, several in silico tools^{20–26} and guidelines²⁷ have been developed, although their specific applicability to the accurate and comprehensive interpretation of the diverse pathogenic mechanism of 5'UTR variants is yet to be fully established. A clear instance of both the effectiveness and remaining challenges of clinical large-scale genome analyses can be found in inherited retinal diseases (IRDs)²⁸⁻³¹. IRDs comprise a genetically and phenotypically diverse constellation of visually debilitating conditions affecting over 2 million people globally^{32,33}. With over 290 known disease genes³⁴, diverse modes of inheritance²⁹, intersecting phenotypes^{35,36}, and available automated approaches to variant interpretation, establishing a genetic diagnosis in IRD patients can be challenging. Even after the use of unbiased approaches such as whole exome (WES) and whole genome sequencing (WGS), up to 50% of cases remain unsolved 15,28,37-39, and hence without the possibility of potential clinical intervention including gene therapy-based treatments^{40,41}. Recent studies have revealed an important contribution of non-coding variation to IRDs, particularly with the identification of deep-intronic mis-splicing variants^{39,42,51,43–50}. Moreover, there is a growing body of evidence supporting the emerging role of genetic variation affecting cis-regulatory regions in the molecular pathogenesis of IRDs^{45,48,52–56}. However, thus far only a few 5'UTR variants have been reported to be implicated in ocular diseases, including IRDs^{48,53,54,57–59}, but no large-scale studies have been performed yet. In this work, we conducted a systematic evaluation of 5'UTR variation in IRD genes using WGS and WES data derived from two IRD cohorts comprising 2,417 participants of the 100,000 Genomes Project¹² and 1,682 local cases, respectively. Firstly, we obtained a comprehensive

selection of 5'UTRs of the most abundant canonical as well as non-canonical protein-coding IRD gene isoforms by performing transcript-level re-quantification of retinal expression data. We then screened these regions for variants in both IRD cohorts and developed a prioritization strategy to identify candidate pathogenic 5'UTR variants. This allowed us to identify 11 potentially causative 5'UTR variants, 10 of which were found in unsolved cases. Functional validation of the predicted pathogenetic mechanism was performed for 4 of these, further supporting the potential implication in disease for 2 variants. Overall, we show that 5'UTRs represent understudied targets of non-coding variation that can provide novel molecular diagnoses in IRDs and demonstrate the importance of reassessing these regions in existing exome and genome sequencing data.

Methods

Re-analysis of retinal RNA-seq data and selection of retina-enriched isoforms of IRD genes. We retrieved paired-end FASTQ files (GSE115828) derived from human postmortem retina samples characterized by Ratnapriya *et al.*, (2019)⁶⁰. Only samples derived from donor retinas showing no features of age-related macular degeneration were evaluated (n=102). Transcripts were quantified through pseudoalignment by *Kallisto*⁶¹ (v.0.46.1) using default parameters. Abundance estimates in transcripts per million (TPM) for all annotated transcripts (*Ensembl* human release 107) were retrieved. A custom R (v.4.0.2) script was used for annotating each transcript with its corresponding gene and biotype and flagging them as canonical and/or belonging to the Matched Annotation from NCBI and EMBL-EBI (MANE) and MANE Plus Clinical set (version 1.0)⁶². For each group of isoforms belonging to each gene, we computed the average of abundance estimates across all samples and the isoform exhibiting the highest average among its corresponding group was deemed retina-enriched. This dataset was further

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

filtered by retaining only protein-coding isoforms derived from selected genes, namely IRD genes listed in either the Retinal disorders panel (v2.195) from Genomics England PanelApp⁶³ or RetNet (https://sph.uth.edu/retnet/) (Table S1). Additionally, we integrated cap analysis gene expression sequencing (CAGE-seq) data derived from fetal and adult retina (FANTOM5⁶⁴ Robust Peak Set using an expression RLE normalized threshold >1) to evaluate the confidence of the annotated transcription start sites (TSS) of the selected transcripts in retina. To aid tiering of variants, the Genomics England PanelApp⁶³ gene color-coded rating system was used: genes with diagnostic-grade rating, borderline evidence and research candidates were flagged with green, amber, and red, respectively. To further assess the retinaenrichment of specific isoforms, their loci were inspected using an integration of multiple publicly available multi-omics datasets derived from human retina (Table S2). Comparison of 5'UTRs of canonical and non-canonical isoforms and selection of 5'UTR variant search space The exact genomic coordinates of the start and end positions of the 5'UTRs of all genes were downloaded from Ensembl biomart (Human Ensembl Genes 107, GRCh38.p13) and filtered to only include the transcripts defined above. We first assessed the number of exons composing these 5'UTRs to identify which IRD genes have spliced 5'UTRs. For each IRD gene for which a retina-enriched non-canonical isoform was identified, we compared the canonical and noncanonical 5'UTRs and computed their respective overlap. The calculated overlaps were then used to classify these genes into three different categories, namely genes with transcripts displaying: (i) fully distinct 5'UTRs, (ii) partly overlapping 5'UTRs, and (iii) fully overlapping 5'UTRs. For each 5'UTR exon of all selected transcripts, we defined a near-splice region by including 25-bp intronic sequence up- and downstream of its respective splice donor and acceptor sites (excluding promoter and coding sequences). The resulting coordinates were annotated with their corresponding transcript identifier and gene name and stored into a sorted BED file (herein after referred to as 5'UTR analysis file) for downstream variant assessment.

Evaluation of 5'UTR capture by whole-exome sequencing

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

We assessed the performance of exome captures of the selected 5'UTRs based on the designs provided by the kits which were mostly used for the generation of our in-house WES data, namely the SureSelect Human All Exon V6 and SureSelect Human All Exon V7 (Agilent Technologies), as well as a selection of the most recent versions of commonly used kits from 4 different providers: SureSelectXT Human All Exon V8 (Agilent Technologies), KAPA HyperExome V2 (Roche), Twist Exome 2.0 (Twist), Illumina Exome Panel v1.2 (Illumina). BED files containing the genomic coordinates of the capture regions were downloaded from the corresponding design catalogs and intersected with the coordinates of the 5'UTRs of interest using bedtools intersect (v2.26.0)⁶⁵ with default parameters. For uniformity, only the capture regions were used to compare between the different designs. Additionally, for the SureSelect Human All Exon V6 and SureSelect Human All Exon V7 kits (Agilent Technologies) both the strict union of all regions covered by baits and a version padded by ±50bp extending into intronic regions were considered for the intersections. A custom Python (v.3.6.8) script was then used to compute for each IRD gene the length proportion (%) of its 5'UTR captured by these kits.

Search of 5'UTR variants in IRD genes submitted to ClinVar

The ClinVar database (ClinVar) was downloaded in a tab-delimited format⁶⁶ directly from the FTP site (https://ftp.ncbi.nlm.nih.gov/pub/clinvar/; version from 2023-03-18) and pre-filtered to keep only entries from the GRCh38.p13 build. The resulting file was further filtered to

retrieve variants located within the regions defined in the 5'UTR analysis file. Large copy number gain/loss variants extending into coding regions as well as variants with a protein-altering or synonymous annotation for the canonical transcript were removed from this analysis.

Cohort selection

To assess the contribution of 5'UTR genomic variation to IRDs, individuals from two different cohorts were selected for this study: (i) 2,397 participants (2,100 probands) from a sub-cohort of the Rare Disease arm of the 100,000 Genomes Project (Genomics England –GE– cohort) affected by posterior segment abnormalities (**Table S3**); (ii) an IRD sub-cohort of 1,682 cases (1,030 probands) with a WES analysis performed at the Center for Medical Genetics Ghent (CMGG cohort). In both cases, sequencing data aligned to GRCh38 build were included.

The 100,000 Genomes Project Protocol has ethical approval from the HRA Committee East of England – Cambridge South (REC Ref 14/EE/1112). This study was registered with Genomics England within the *Hearing and sight* domain under Research Registry Projects 465. This study was approved by the ethics committee for Ghent University Hospital (B6702021000312) and performed in accordance with the tenets of the Helsinki Declaration and subsequent reviews.

Sequencing and variant analysis

We interrogated WGS and WES data from the two cohorts described above to detect germline single-nucleotide variants (SNVs) and small insertions and deletions (indels) overlapping the regions defined in the *5'UTR analysis file*. The sequencing and bioinformatic pipelines used for processing genome data derived from the participants of the GE cohort have been described previously¹².

Samples from the CMGG cohort were tested using WES with the SureSelect Human All Exon V6, SureSelect Human All Exon V7 (Agilent Technologies) or HyperExome (Roche) enrichment kits and sequenced on HiSeq 3000 or NovaSeq 6000 instruments (paired-end 150 cycles) (Illumina). Reads were aligned to the human reference genome (GRCh38 build) with *BWA* (v0.7.15)⁶⁷ and *GATK HaplotypeCaller* (v3.82)⁶⁸ was used for calling SNVs and indels. Resulting variant call format (VCF) files from both cohorts were subsequently parsed based on the regions of interest using *BCFtools* (v1.9)⁶⁹. Only variants satisfying the filter criteria for sequencing depth (DP>10) and genotype quality (GQ>15) were retrieved.

Variant annotation and prioritization

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

From each cohort, a file containing unique variants was created and formatted so that it could be annotated with the Ensembl Variant Effect Predictor⁷⁰ (VEP, release 107). Apart from gene and transcript information, each variant was annotated with frequency data retrieved from gnomAD⁷¹ allele frequencies, splicing (dbscSNV⁷², SpliceAl²³, (genomes, v3.1.2) MaxEntScan⁷³), pathogenicity predictions (EVE⁷⁴, CADD⁷⁵), and regulatory data⁷⁶. The recently developed *UTRannotator*²⁰ tool was used to annotate variants that create or disrupt uORFs. The classical⁷⁷ and retinal⁷⁸ Kozak consensus sequences were considered altered when variants were identified within the position range -1 to -10 relative to the main AUG (canonical start codon). In addition, nucleotide frequency plots corresponding to the Kozak sequences of the retina-enriched and not retina-enriched transcripts evaluated in this study were generated using were generated with WebLogo⁷⁹ (v.3.7.12). Annotation data tables containing predicted changes in translational efficiency⁸⁰ and secondary structure minimum free energy affecting double-stranded RNA or G4 quadruplex structures⁸¹ were downloaded (5utr ['suter']: https://github.com/leklab/5utr) and queried for the variant positions using tabix⁸² (v.1.7-2); further evaluation of changes in mRNA secondary structure was performed using the *Ufold*⁸³

(v.1.2), REDfold⁸⁴ (v1.14.alpha), and MXfold2⁸⁵ (v0.1.2) tools. To assess whether variants were located within TSS relevant to retinal gene expression, we made use of the CAGE-seq data described above. Translation initiation-related feature data from the Human Internal Ribosome Entry Sites (IRES) Atlas⁸⁶ was also queried to annotate variants found within these regions involved in cap-independent translation initiation. Annotated 5'UTR variants were classified into the following 7 categories: (i) uAUG gained, (ii) change in existing uORF, (iii) alteration of classical or retinal primary Kozak context, (iv) splicing, (v) change in translational efficiency (TE), (vi) change in secondary structure minimum free energy, and (vii) overlapping a retinal transcription start site and/or an IRES. Variants were first selected when their minor allele frequency was lower than 2% in all populations. The resulting variants were further filtered using specific criteria for each category: (i) uAUG created in a strong or moderate Kozak context, (ii) natural uAUG loss, (iii) variant located in positions -3, -4, -5, -6, or -9, (iv) any SpliceAl Delta Score (DS_AG, DS_AL, DS_DG, DS_DL) higher than 0.2, (v) |log2FC|≥0.5, (vi) |FC| ≥1.5, (vii) variant located within a TSS or IRES. Variants for which the inheritance pattern and phenotype of the patient were compatible with the gene in which the 5'UTR variant was identified were selected as candidates. This prioritization procedure is depicted in Figure 1. For comparing the proportion of variants for each category between cohorts, the statistical analysis was performed in R using the χ^2 -test. Finally, for each candidate variant identified in unsolved cases, an additional screening was performed to discard (likely) pathogenic variants, both SNVs and structural variants (SVs), in other IRD genes that could provide an alternative molecular diagnosis. For the cases from the GE cohort in which the identified 5'UTR variant remained as candidate, we requested to have a clinical collaboration with Genomics England.

Cell culture

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

ARPE-19 (ATCC, CRL-2302™) and HEK-293T cells (ATCC CRL-3216™) cells were grown in either Dulbecco's minimal essential medium (DMEM) with phenol red (Thermo Scientific Life Technologies) or DMEM:F12 (Gibco) medium supplemented with 10% fetal bovine serum (Gibco), 1% penicillin-streptomycin (Gibco), 1% non-essential amino acid solution (Gibco), and 0.1% amphotericin B (Gibco), respectively. Cells were cultured at 37°C and 5% CO2 and tested for mycoplasma contamination prior to use.

To perform functional studies of the identified 5′UTR *ARL3* variant, lymphocytes from affected carriers (n=2) were isolated from EDTA blood using Lymphoprep (STEMCELL technologies). For each sample two cultures were started in RPMI medium with 10% fetal bovine serum and substituted with interleukin-2 and phytohaemagglutinin. One of both cultures was treated for four hours with puromycin (200 μg/mL) prior to RNA extraction to suppress nonsensemediated decay.

Cloning and mutagenesis

In order to evaluate the functional effect of 3 selected 5'UTRs variants (*RDH12*:c.-123C>T, *MERTK*:c.-125G>A, *PAX6*:c.-44C>T), we cloned the wild-type 5'UTR of interest (IDT gBlock) into a psiCHECK™-2 dual luciferase vector (Promega) using the Cold Fusion cloning kit (Sanbio BV). The recombinant vectors were then amplified in One Shot TOP10 Chemically Competent *E. coli* cells (Invitrogen) and purified using the NucleoBond Xtra Midi kit (Filter Service S.A). For the generation of the overexpression construct to further assess the *RDH12*:c.-123C>T variant, we designed a gBlocks™ fragment comprising the wild-type 5'UTR and coding sequence (CDS) of *RDH12*; both sequences were modified to include downstream Myc and FLAG in-frame tags to evaluate the translation of the uORF introduced by the *RDH12*:c.-123C>T variant and RDH12 protein levels, respectively. These fragments were then cloned into a pcDNA™3.1⁽⁺⁾ (Invitrogen) vector by restriction-ligation cloning and the recombinant vectors were amplified

and purified as described above. For all constructs, 5'UTRs variants were introduced using the Q5 Site-Directed Mutagenesis Kit (NEB) using variant-specific primers designed with the *NEBaseChanger* tool. The sequence of each insert was confirmed by Sanger sequencing using the BigDye Terminator v3.1 kit (Life Technologies) and/or long-read whole plasmid sequencing (Plasmidsaurus). A schematic overview of these constructs is shown in **Figure S1**. All primer sequences can be found in **Table S4**.

Dual luciferase assays

ARPE-19 cells were seeded in a 24-well plate (Greiner Bio-One BVBA) at a density of 50,000 cells/well in 1mL of medium without antibiotics to reach 70-90% confluence at transfection (18-24h after plating). Cells were transfected at a 3:1 reagent to plasmid DNA ratio using the TransIT-X2® Dynamic Delivery System (Mirus Bio) according to the manufacturer's instructions. After 24 h, cells were lysed, and luciferase activity was detected using the Dual-Glo® Luciferase Assay System (Promega) in a Glomax 96-Microplate Luminometer (Promega). Each transfection was performed in triplicate and each experiment was repeated at least three times to ensure reproducibility. For each well, the ratio of *Renilla* luciferase activity was normalized to *Firefly* luciferase activity. A custom R script was used to evaluate the effect of each variant on luciferase activity through a linear mixed effects model (implemented in the *Ime4* package⁸⁷) having set the luciferase vector as fixed effect and the biological replicate as random effect.

RNA isolation and quantitative polymerase chain reaction (qPCR)

Total RNA was extracted using either the RNeasy Mini kit® (Qiagen) (ARPE-19 and HEK-293T cells) or the Maxwell RSC simply RNA kit (Promega) (cultured lymphocytes) according to the manufacturer's instructions. Isolated RNA underwent DNase treatment (ArcticZymes, Tromsø,

Norway) prior to cDNA synthesis with the iScript cDNA Synthesis Kit (Bio-Rad Laboratories). For each cDNA sample, qPCR assays were prepared using SsoAdvanced Universal SYBR Green Supermix (Bio-Rad Laboratories) and run on LightCycler 480 System (Roche). Data were analyzed with *qbase+*88 (CellCarta, v.3.4) and normalized either to a set of housekeeping genes (*YWHAZ*, *HPRT1*, *HMBS*, *SDHA*) or *Firefly* luciferase for normalization of *Renilla* luciferase mRNA levels. All primer sequences can be found in **Table S4**. Statistical analyses were performed in R using the Wilcoxon rank sum test.

Overexpression and immunoblotting

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

To perform immunoblotting of RDH12 and the predicted peptide encoded by the uORF introduced by the RDH12:c.-123C>T variant, ARPE-19 cells were seeded in 12-well plates (Greiner Bio-One BVBA) at a density of 100,000 cells/well, allowed to settle overnight, and then transfected with the wild-type and mutant RDH12 overexpression vectors using the TransIT-X2® Dynamic Delivery System (Mirus Bio) according to the manufacturer's instructions. The pcDNA™3.1(+) (Invitrogen) backbone vector was transfected as negative control. Four hours prior to RNA and protein isolation, cells were treated with 10µM MG-132 proteasome inhibitor (Merck Life Science). For total protein extraction, cells were lysed with RIPA Buffer (Sigma-Aldrich) including protease inhibitory cocktail (Roche Diagnostics), phosphatase inhibitory cocktail 2, and phosphatase inhibitory cocktail 3 (Sigma-Aldrich). Protein concentrations were measured using the Pierce™ BCA Protein Assay kit (Fisher Scientific). After centrifugation and reduction with 1M DTT (Sigma-Aldrich), protein lysates were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis using either NuPAGE™ 4–12% Bis-Tris (RDH12 blot) or Novex™ 16% Tricine (uORF blot) Protein Gels (Fisher Scientific) with a ladder (Precision Plus Protein All Blue Standards, Bio-Rad Laboratories). Proteins were then transferred to a nitrocellulose membrane using the iBlot 2 Dry Blotting System (Thermo Fisher Scientific). Membranes were blocked for 2 hours at room temperature in 2% ECL™ Blocking Agent (Cytiva Amersham) and incubated at 4°C overnight with anti-FLAG (1:1000, F1804, Merck Life Science) or anti-Myc (1:1000, ab9106, Abcam) primary antibodies. Membranes were subsequently incubated for 2 hours at room temperature with the appropriate horseradish-peroxidase-conjugated secondary antibody (1:2500, 7076S or 7074S, Cell Signaling Technologies) and revealed with the SuperSignal™ West Dura Extended Duration Substrate (Fisher Scientific). Membranes were scanned with an Amersham Imager 680 system (GE Healthcare Life Sciences). Protein quantification was performed by firstly stripping the membranes with Restore™ PLUS Western Blot Stripping Buffer (Thermo Scientific), incubating them for 1 hour at room temperature with a primary antibody against β-tubulin (1:2500, ab6046, Abcam) and for 2 hours with a horseradish-peroxidase-conjugated secondary antibody (1:2500, 7074S, Cell Signaling Technologies). RDH12 (FLAG) signal intensity quantification was achieved using *ImageJ* (NIH, v.1.50i) and normalized to the amount of βtubulin. To further assess the translation of the peptide encoded by the uORF introduced by the RDH12:c.-123C>T variant, transfected HEK-293T cells were lysed as previously described, and protein lysates incubated at 4°C overnight with Dynabeads Protein A (Thermo Fisher Scientific), to which the anti-Myc primary antibody (1:1000, ab9106, Abcam) was bound. Bound proteins were subsequently eluted and subjected to anti-Myc Western Blot analysis as described above. Statistical analyses were performed in R using the Student's t-test.

Screening of *RDH12*: c.-123C>T variant

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

The *RDH12*:c.-123C>T 5'UTR variant was shared with members of the European Retinal Disease Consortium (ERDC: https://www.erdc.info/) to evaluate its pathogenicity and identify

additional carriers of the *RDH12*:c.701G>A (p.Arg234His) missense variant to confirm its *cis*-configuration. Primer sequences for PCR and Sanger sequencing are listed in **Table S4**.

Results

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

Isoform-level re-quantification of retinal gene expression reveals differential 5'UTRs of IRD

genes

To obtain a relevant selection of 5'UTRs for downstream variant screening, we performed a transcript-level re-analysis of RNA-seq data to identify protein-coding non-canonical isoforms with relevant retinal expression i.e., higher than its respective canonical isoform, to be retained in addition to the canonical isoforms. A total of 454 canonical and non-canonical transcripts belonging to 378 IRD genes were thus selected (with maximum of 2 isoforms per gene) (Table S5), from which their 5'UTRs were retrieved, resulting in 638 genomic regions (Table S6). Considering these 454 transcripts, the 5'UTRs of approximately 62% of IRD genes (233/378) are only part of the first coding exon while 33% of IRD genes (126/378) have exclusively transcripts with spliced 5'UTRs, i.e., their 5'UTR comprise additional full non-coding exons. A minor fraction (19/378) of genes has isoforms with both spliced and non-spliced 5'UTRs (Figure 2A; Table S7). Of the 76 IRD genes for which a retina-enriched non-canonical isoform was identified, 20 display a fully distinct 5'UTR compared to the one of their corresponding canonical isoforms (Figure 2B; Table S8). For six of these, the non-canonical TSS is further supported by CAGE-seq data derived from both adult and fetal retina (Table S5; Figure S2). Two remarkable examples are CRB1 and RIMS2, for which the non-canonical isoforms (ENST00000681519.1: 48.38±14.97 TPM; ENST00000436393.6: 41.58±12.35 TPM) were found to be more abundant in retina compared to their respective canonical isoforms (ENST00000367400.8: 2.54±3.88 TPM; ENST00000696799.1: 12.19±3.85 TPM). These findings

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

were also supported by the integration of multiple multi-omics datasets derived from human retina (Figure S3; Table S2). A substantial fraction of 5'UTRs can be captured by whole-exome sequencing In view of the large volume of existing WES data, we evaluated the performance of six recent and commonly used commercial exome capture designs from four different providers on the selected 5'UTRs of IRD genes. The kits considered in this analysis were found to display a variable performance with an average coverage of the selected 5'UTRs ranging from 7% (Twist Exome 2.0) to 39% (Illumina Exome Panel v1.2) (Figure 3A; Table S9). Besides, the fraction of IRD genes with 5'UTRs fully captured ranged from 3% (10/378) to 20% (73/378). Regarding the kits that were mostly used in-house (SureSelect Human All Exon V6 and SureSelect Human All Exon V7), although a slightly higher 5'UTR capture was observed for the kit with a higher amount of probes (SureSelect Human All Exon V6) (Figure S4; Table S10), we found that approximately 15% of IRD genes (57/378) have the selected 5'UTRs fully captured. This fraction increased up to 39% (148/378) (Figure 3B; Table S10) if a padded bait design, including all regions that can be confidently genotyped, was considered. A retrospective analysis of 5'UTR variants reported in IRD genes reveals a majority classified as Variants of Uncertain Significance (VUS) A total of 1,547 5'UTR variants in IRD genes have been submitted to the ClinVar database thus far (Table S11). All variants except 4 have been clinically interpreted. Only 2% (31/1,547) of the variants have been classified as pathogenic or likely pathogenic, of which 32% (10/31) and 16% (5/31) were found in the PAX6 and NMNAT1 genes, respectively. On the other hand, 34% (527/1,547) of the 5'UTR variants have been classified as benign or likely benign, of which no single gene was found to account for more than 5% of these variants. While 5% (81/1,547) of the variants had conflicting interpretations of pathogenicity, the largest fraction comprising 58% (904/1,547) of all variants have been classified as VUS.

Analysis of 5'UTRs in WGS and WES data of two IRD cohorts reveals rare and ultra-rare

variants predicted to affect 5'UTR function

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

To systematically assess the contribution of 5'UTR genomic variation to IRDs, we performed a variant analysis within the selected 643 genomic regions in affected individuals from two different IRD sub-cohorts, namely the GE (n=2,397 WGS) and CMGG (n=1,682 WES) cohorts. We identified a total of 2,898 and 381 distinct 5'UTR variants within the GE and CMGG cohorts, respectively. The majority of these variants (2,637/2,898 and 334/381) had a minor allele frequency (MAF) lower than 2% in all populations and a substantial fraction (506/2,898 and 92/381) was found to be absent from all reference population public databases. To aid the interpretation of these 5'UTR variants, we classified them into 7 (non-mutually exclusive) categories according to their in silico predicted functional consequences (Figure 1). A summarized overview of the number of variants that remained after classification and category-specific filtering can be found in Table 1. Out of the 1,450 remaining variants (Dataset S1), 370 were present in more than one category. Of the remaining variants assigned to a single category, the bulk corresponded to variants overlapping a retinal TSS or an IRES (761/1,450; 221 -TSS-, 488 -IRES-, 52 -TSS & IRES-), followed by variants with a predicted change in secondary structure minimum free energy (204/1,450). When comparing the number of variants in each category between the two cohorts, we observed statistically significant differences in the number of variants overlapping a retinal TSS and/or IRES, for which the proportion of variants was higher for the WGS-based GE cohort compared to the WES-based CMGG cohort (~55% and ~35% respectively, p<0.05). These differences are most likely due to the expanded capture of regions including TSS allowed by the use of WGS in the

GE cohort. Additionally, it is noteworthy that for the IRD genes with 5'UTRs harboring IRES (92/378), these elements were found to span on average 61% of the 5'UTR and even its entire length for certain genes (12/92) (**Table S12**).

Table 1. Summarized overview of the number of 5'UTR variants that remained after functional classification and filtering.

	GE cohort	CMGG cohort	Total	%
uAUG gained	30	5	35	2.41
Change in existing uORF	17	1	18	1.24
Alteration of classical or retinal primary Kozak context	16	6	22	1.52
Splicing	29	10	39	2.69
Change in translational efficiency	1	0	1	0.07
Change in secondary structure minimum free energy	194	10	204	14.07
Overlapping a retinal transcription start site or an IRES	692	69	761	52.48
> 1 category	276	94	370	25.52
Total	1255	195	1450	

Abbreviations: CMGG, Center for Medical Genetics Ghent; GE, Genomics England; IRES, internal ribosomal entry site; uORF, upstream open reading frame.

Systematic variant evaluation allows the prioritization of candidate pathogenic 5'UTR variants

To enhance the likelihood of identifying potential pathogenic 5'UTR variants, we prioritized the ones with higher predicted impact based on specific criteria for each category (**Figure 1**) and for which the inheritance patterns and reported phenotypes fitted the genes in which the 5'UTR variants had been identified. The application of this prioritization procedure is illustrated in **Table S13**. We prioritized 11 candidate pathogenic 5'UTR variants. Of these, 10 were found in unsolved cases and 8 have not been reported before. Of note, although initially identified through WGS, 6 of these variants would also be covered by WES. An overview of

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

the genetic, phenotypic, and in silico prediction details of these variants is shown in Table 2. The pedigrees of these families including variant segregation are shown in Figure S5. Four of these variants were found to alter splicing in genes linked to autosomal dominant (PRPF31), autosomal recessive (NMNAT1) and X-linked (NDP) disease. The NDP:c.-70G>A and PRPF31:c.-9+1G>A variants have recently been reported by Daich Varela et al. (2022)⁴⁸. We identified a de novo variant (PRPF31:c.-9+1G>T) in the same 5'UTR position of PRPF31 in a sporadic case with rod-cone dystrophy in which bi-allelic GRM6 variants had been identified, one of them reported as likely benign (Table \$14). Variants in GRM6 cause autosomal recessive congenital stationary night blindness⁸⁹, which is different from the clinical diagnosis in this proband. The NMNAT1:c.-57G>A variant was found in an individual with macular dystrophy that carries in trans an extremely rare missense variant for which in silico predictions support a pathogenic effect. Changes in secondary structure were predicted for 4 variants in genes linked to autosomal dominant (ARL3, PAX6) and autosomal recessive (MERTK, RD3) disease (Figure S6). Given the inheritance pattern and in silico predictions, a gain-of-function effect was hypothesized for the ARL3:c.-88G>A and PAX6:c.-44T>C variants. Both the MERTK:c.-125G>A and RD3:c.-394G>A variants were identified in homozygous state and found to overlap their respective TSS. The introduction of an uORF was predicted for 2 variants in the NPHP4 and RDH12 genes. In contrast to the uORF created by the RDH12:c.-123C>T variant, the one introduced by the NPHP4:c.-21C>T variant is out-of-frame and overlaps the CDS. Although no segregation could be established for this case with non-syndromic rod-cone dystrophy, an ultra-rare missense NPHP4 variant with pathogenic in silico predictions was identified.

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

Only one variant in a gene linked to dominant disease (PRPF4) was predicted to affect the primary Kozak consensus sequence. The PRPF4:c.-6C>T variant results in a transition to an infrequent nucleotide at this position within the Kozak consensus sequences derived from the IRD gene isoforms selected in this study (Figure S7). This variant was found in a sporadic case with rod-cone dystrophy in which 2 likely pathogenic variants have been identified in the ITF140 gene (Table \$14); segregation analysis was not possible to establish the phase of any of these alleles. Four of the variants (ARL3:c.-88G>A, MERTK:c.-125G>A, PAX6:c.-44T>C, RDH12:c.-123C>T) were selected for functional validation using diverse multiple experimental approaches. Downstream functional analyses support the pathogenicity of the MERTK:c.-125G>A and RDH12:c.-123C>T variants Depending on the tissue-specific gene expression and availability of patient material, we conducted either in vitro evaluation in ARPE-19 cells (dual luciferase assays or overexpression), or mRNA expression analysis in patient-derived lymphocyte cultures (Figure 4A). The RDH12:c.-123C>T and MERTK:c.-125G>A variants were found to result in a significant decrease in luciferase activity (Figure 4B). To further elucidate the underlying mechanism, Renilla mRNA expression analysis was performed. Relative Renilla luciferase mRNA levels remain unchanged for RDH12:c.-123C>T, whereas a significant decrease was observed for MERTK:c.-125G>A (Figure 4C), hence suggesting a translational and a transcriptional effect for these variants, respectively. Taking advantage of the expression of ARL3 in accessible tissues, we performed qPCR-based quantification of ARL3 mRNA abundance in lymphocyte cDNA from the two affected siblings in whom we identified the ARL3:c.-88G>A variant and five healthy controls. No significant differences were observed in ARL3 mRNA abundance between the affected carriers and

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

controls (Figure 4D). Interestingly, ARL3 expression levels were slightly higher in the patient samples derived from the lymphocyte cultures treated with puromycin, a translation inhibitor used to suppress nonsense-mediated mRNA decay, compared to the corresponding untreated samples and controls. Therefore, although the ARL3:c.-88G>A variant was not predicted to affect splicing, we also performed Sanger sequencing on the cDNA derived from the puromycin-treated and untreated patient lymphocyte cultures. Neither splicing defects nor allele-specific expression were observed (data not shown). In view of the negative results obtained for the PAX6:c.-44T>C and ARL3:c.-88G>A variants, the phenotypes of patients F9 and F10 were re-evaluated. Neither anterior segment abnormalities nor other clinical presentations compatible with a PAX6-related disease were observed in patient F9 or her affected relatives. Regarding F10, re-evaluation of one of the affected siblings revealed an acquired vascular ocular condition instead of an IRD. The RDH12:c.-123C>T 5'UTR variant is found always in cis with the p.Arg234His hypomorphic allele and results in reduced RDH12 protein levels We identified the RDH12:c.-123C>T variant in one solved case from the GE cohort characterized by bi-allelic RDH12 coding variants (c.[701G>A];[c.735 743del], p.[Arg234His]; [Cys245 Leu247del]). The 5'UTR variant, reported as VUS in ClinVar, was found in cis with the p.Arg234His allele. Further evaluation of this 5'UTR variant in 10 additional RDH12 bi-allelic patients from 8 families carrying the p.Arg234His variant revealed that the c.-123C>T and p.Arg234His variants always form a complex allele (Table S15). This was also shown for 7 carriers of the p.Arg234His variant affected by other pathologies (data not shown). Here, we report the first patient who is homozygous for the RDH12: c.[-123C>T];[701G>A] complex allele (**Table S15**). Compared to other patients carrying the 5'UTR variant in trans with a null *RDH12* allele³⁰, patient F21 presents with a milder phenotype (mild decreased acuity (20/25 OD and OS) in fourth decade of life, foveal sparing maculopathy with a circumscribed area of atrophy within the vascular arcades, without a nasal component.

The c.-123C>T variant is predicted to introduce an uAUG into a strong Kozak consensus sequence that is in-frame with a stop codon located 75 nucleotides downstream in the 5'UTR. In view of the results obtained in the luciferase assays and the predicted uORF-introducing effect of the 5'UTR variant, we further inspected the potentially exclusive effect at the translational level by assessing RDH12 mRNA abundance and protein levels in an overexpression setting. Although we could not confirm translation of the 25-amino-acid-long peptide predicted to be encoded by the uORF by co-immunoprecipitation (*data not shown*), we observed unaltered mRNA but significantly (p<0.05) reduced RDH12 protein levels, thereby providing further evidence for a post-transcriptional or translational effect (**Figure 4E-F**) which was already suggested by the mRNA evaluation in the luciferase assays.

Discussion

Given the emerging role of non-coding variation underlying IRDs^{45,48,52–55} and the essential regulatory function of 5'UTRs^{2,6}, we set out to evaluate their contribution to this heterogeneous group of disorders by analyzing, systematically annotating, filtering and prioritizing 5'UTR variants in two large IRD cohorts in combination with different experimental approaches for functional validation.

Thus far, only a few studies have implicated 5'UTR variation in the molecular pathogenesis of IRD cases^{48,53,54}. Our retrospective analysis of 5'UTR variants in IRD genes listed in the ClinVar database⁶⁶ revealed that as many as 58% of all variants have been classified as VUS. A large fraction of the underrepresentation of (likely) pathogenic 5'UTR variants in clinical databases

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

can be explained by their exclusion from downstream tiering pipelines, which prioritize variants with protein-altering consequences and hence neglect the potential impact of 5'UTR variants⁹¹. Furthermore, the identification of these variants is not always feasible by means of commercial exome enrichment platforms, in particular when variants are found within 5'UTR exons that are not part of or proximal to the first protein-coding exon¹⁹. Here, we show that the enriched 5'UTR fraction is highly dependent on the WES capture kit used, and ranges from 7% to 39%. Overall, as previous studies have also argued^{92–94}, our analysis underscores the diagnostic value of re-analyzing exome data, in which causative variants might already be present but previously disregarded. Furthermore, the identification of the genetic defects underlying IRDs is greatly impacted by the inherent complexity of the retinal transcriptional landscape. Variants in retina-enriched isoforms and tissue-specific mis-splicing have been shown to be important molecular mechanisms underpinning disease pathogenesis and phenotypic heterogeneity^{95–99}. As gene isoforms can display differential 5'UTRs that can result in differential translational efficiencies¹⁰⁰, we performed a transcript-level re-analysis of retinal expression data to obtain a relevant selection of 5'UTRs of IRD genes for downstream variant analysis. We identified 76 IRD genes with alternative isoforms exhibiting retinal expression levels higher than their respective canonical isoforms, of which 20 displayed a fully distinct 5'UTR. This analysis also found the recently identified photoreceptor-specific non-canonical CRB1 isoform, which bears a unique 5'UTR exon¹⁰¹. Similarly, we confirmed the retinal enrichment of an alternative RIMS2 isoform containing an unconventional 5'UTR exon, which has been shown to be photoreceptor-specific and functionally conserved in mouse (Del Pozo-Valero et al., unpublished data). By revealing that a significant fraction of IRD genes express alternative

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

retinal isoforms, our analysis highlights the importance of isoform-aware variant annotation for adequate interpretation. To aid the assessment of 5'UTR variant pathogenicity, in silico tools have recently been developed, with an emphasis put on uORF-perturbing variants^{20,26}. A systematic characterization of this class of 5'UTR variants showed that they are subject to strong negative selection, which could even be equivalent to that observed against missense variants¹¹. However, thus far, these tools do not provide comprehensive annotations of all possible effects 5'UTR variants can exert8. Here, we designed an integrative annotation of 5'UTRinformative features and built a prioritization strategy combining family and phenotypic data to increase the probability of identifying potential pathogenic 5'UTR variants. Although we performed these analyses in IRD cohorts, the features evaluated, and the methods presented in this study can be extrapolated and applied in any setting involving clinical interpretation of 5'UTR variation. We prioritized 11 candidate pathogenic 5'UTR variants. The great majority of these variants (8/11) have not been reported before, most likely due to their exclusion from routine prioritization pipelines and subsequent clinical interpretation⁹¹. These 11 variants were assigned to 5 of the 7 categories we defined to classify their potential functional consequences, thus reflecting the diversity in predicted functional effect. Of note, the majority (4/11) was predicted to have an effect on splicing which, in line with our analysis revealing that almost one third of all IRD genes have their 5'UTRs spliced, supports that these regions are also susceptible to disease-causing splicing defects. Notably, we also provided a set of filtered annotated 5'UTR variants with in silico predictions pointing to a pathogenic effect that were not prioritized as candidates due to inconsistent genotypes or phenotypes in the patients evaluated. Therefore, we cannot dismiss the possibility that these variants can have a

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

pathogenic effect when present in the right context, e.g. in trans with a second pathogenic allele in a gene linked to recessive disease. Given the particular importance of providing functional evidence to support the pathogenicity of variants located within non-coding regions, we evaluated the predicted functional consequence of 4 candidate variants. Despite the extreme rarity and disease co-segregation of the PAX6:c.-44C>T variant, both the lack of functional evidence and the unusual phenotype established upon clinical re-evaluation indicate that this variant is not explaining the phenotype. Likewise, we could not confirm the predicted effect of the ARL3:c.-88G>A variant using accessible patient-derived material. The sibling of the proband was eventually considered not affected by an IRD, indicating that the variant is either not causative, incompletely penetrant, or simply a recessive allele. Interestingly, a phenotype similar to that of the proband has been associated with a pathogenic variant in this gene¹⁰², which could suggest that this variant exerts a retina-specific effect that cannot be evaluated with the current experimental setting. Nevertheless, it is important to note that in this case both siblings have been studied by WES, but were not tested for known deep-intronic and structural variants. Before proceeding with further functional characterization of the ARL3:c.-88G>A variant, WGS should thus be performed to confirm or rule out such variants. Altogether, these results highlight the need and potential limitations of experimental assays to validate the functionality of non-coding variants. We could provide a novel molecular diagnosis in a patient with severe early-onset retinal dystrophy that remained unsolved after WGS screening. This individual was found to be a homozygous carrier for the extremely rare c.-125G>A variant in MERTK, overlapping its transcription start site, for which our in silico predictions pointed to an effect at the transcriptional level. A drastic reduction of luciferase activity accompanied by decreased

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

relative Renilla luciferase mRNA levels confirmed the hypothesized transcriptional effect of the variant, which is consistent with a loss of function of MERTK. To our knowledge, this is the first reported disease-causing 5'UTR variant in MERTK. One of the candidate pathogenic 5'UTR variants was found in a case solved with bi-allelic RDH12 coding variants, namely the p.Arg234His hypomorphic missense^{90,103,104} and the p.Cys245 Leu247del in-frame variants. The identified c.-123C>T 5'UTR variant was found in cis with p.Arg234His, both in this case as well as in 10 additional RDH12 bi-allelic patients screened for this 5'UTR variant, with one of them being homozygous for this complex allele. The pathogenicity of p.Arg234His has been questioned in view of functional assays revealing RDH12 protein levels and catalytic activity comparable to the wild-type or polymorphic alleles, respectively¹⁰⁵. We therefore hypothesized a pathogenic effect exerted by the RDH12:c.-123C>T variant as part of this complex allele. This 5'UTR variant was predicted to introduce an upstream start codon (uAUG) into a strong Kozak consensus, thereby creating an uORF. Given that ribosomes would first encounter and start translating from this gained uAUG, we hypothesized that this variant would decrease normal RDH12 translation and thus result in lower protein levels. Furthermore, this variant has been argued to affect the function of an alternative promoter of RDH12 based on the observed decreased activity in a luciferase reporter assay⁵². Importantly, this experimental setup did not include comparison between mRNA levels and luciferase protein activity and was therefore unable to pinpoint at which level the effect occurs. Here, using a dual luciferase assay with the 5'UTR instead of the genomic sequence, followed by downstream evaluation at both the mRNA and protein level, we confirmed the hypothesized uORF-mediated effect. We tested this hypothesis further using an overexpression setting and demonstrated unaltered mRNA but significantly reduced RDH12 protein levels, hence confirming the translational effect of RDH12:c.-123C>T variant.

Although we could not obtain experimental evidence supporting the translation of the uORF-encoded peptide, which might suggest its instability, we cannot rule out alternative mechanisms such as ribosome stalling⁹. However, further studies are needed to confirm this hypothesis. Overall, our results indicate that not p.Arg234His alone, but rather the combination of p.Arg234His and c.-123C>T, or even c.-123C>T by itself, is disease-causing (Figure 5).

Conclusions

5'UTRs are essential modulators of post-transcriptional and translational control. Even though they can be captured by WES to a large extent, variants within these regions are typically overlooked in both research and routine clinical settings, mainly due to their challenging interpretation. In this study, we developed a systematic strategy to comprehensively annotate and prioritize 5'UTR variants in IRD genes. This strategy combined with functional studies allowed us to pinpoint 5'UTR variants providing either novel molecular diagnoses or the full picture explaining the pathogenicity of previously reported hypomorphic variants. Overall, in this study we highlight the importance of multi-layered annotation and validation of noncoding variation potentially underlying disease and provide a 5'UTR interpretation approach that could be extrapolated to other rare diseases.

663	Abbreviations
664	5'UTR: 5' untranslated region
665	AD: Autosomal dominant
666	AR: Autosomal recessive
667	CAGE-seq: Cap analysis gene expression sequencing
668	CMGG: Center for Medical Genetics Ghent
669	CDS: Coding sequence
670	DMEM: Dulbecco's minimal essential medium
671	ERDC: European Retinal Disease Consortium
672	FC: Fold change
673	GE: Genomics England
674	IRD: Inherited retinal disease
675	IRES : Internal ribosomal entry sites
676	MAF: Minor allele frequency
677	OD/OS: Oculus dexter/sinister (right/left eye)
678	qPCR: Quantitative polymerase chain reaction
679	SNV: Single-nucleotide variant
680	SV: Structural variant
681	TSS: Transcription start site
682	TPM: Transcripts per million
683	TE: Translational efficiency
684	uORF: Upstream open reading frame
685	VUS: Variant of uncertain significance
686	WES/WGS: Whole exome/genome sequencing




Figure 1. Functional annotation of 5'UTR variants, filtering, and prioritization strategy followed in this study. A combination of *in silico* tools (*see Methods*) was used to annotate 5'UTR variants, which were then classified into 7 functional categories. For each of these categories, specific criteria were established for prioritizing variants with a more likely functional impact (*bottom*). Only variants with a minor allele frequency (MAF) <2% were further studied. The following information was then reviewed: inheritance pattern of the family (AR including sporadic cases; AD; XL) and clinical features. For the selection of candidate variants, both had to be in agreement with the reported mode of inheritance and phenotype associated with the gene in which the 5'UTR variant was found. Abbreviations: AD: autosomal dominant; AR: autosomal recessive; FC: fold change; IRES: internal ribosomal entry site; TE: translational efficiency; TSS: transcription start site; uAUG: upstream AUG; uORF: upstream open reading frame.




Figure 2. Characterization of 5'UTRs of IRD genes. (A) Representation of the proportion of IRD gene isoforms based on the structure of their 5'UTRs. **(B)** Classification of IRD genes with a retina-enriched isoform differing to the canonical one based on the comparison of their respective 5'UTRs.




Figure 3. Evaluation of 5'UTR capture by whole-exome sequencing (WES). (A) Boxplots showing the capture performance (*x-axis*) of commonly used commercial exome capture designs on the selected 5'UTRs. The kits that were mostly used for the generation of our in-house WES data are highlighted in *darker gray*. (B) Histogram representing the portions of 5'UTRs (*y-axis*) of the selected IRD genes which are captured by the SureSelect Human All Exon V6 kit (Agilent Technologies) considering a *strict* or a *padded* design (*see Methods*).




Figure 4. Functional evaluation of candidate pathogenic 5'UTR variants in the *ARL3*, *MERTK*, *PAX6*, and *RDH12* genes. (A) Various approaches were used for functionally evaluating candidate variants, including *in vitro* studies (dual luciferase reporter assays and overexpression) and experiments with clinically-accessible tissues (expression analysis in patient-derived lymphocytes). (B) Results from the luciferase assays for the *MERTK*:c.-125G>A, *PAX6*:c.-44C>T, and *RDH12*:c.-123C>T variants. The bar

plot shows, for each variant, the fold change (FC) of the luciferase reporter level relative to the level of their corresponding wild-type (WT) construct luciferase vector (FC= 1). The *RDH12*:c.-123C>T and *MERTK*: c.-125G>A variants resulted in significant (p<0.001) decrease in luciferase activity (~92% and ~99%, respectively). (C) Relative *Renilla* luciferase mRNA levels were significantly decreased (~42%, p<0.01) for the *MERTK*:c.-125G>A variant while they remain the same for the *RDH12*:c.-123C>T variant when normalized to mRNA of *Firefly* luciferase and compared to their corresponding wild-type (WT) construct luciferase vectors. (D) qPCR quantification of *ARL3* mRNA abundance in lymphocyte cDNA of two affected siblings carrying the *ARL3*:c.-88G>A novel variant and five healthy controls. No significant differences were observed in *ARL3* mRNA abundance between the affected carriers and controls. (E-F) Using an overexpression setting, the *RDH12*:c.-123C>T variant was shown to result in (E) unaltered mRNA levels but (F) significantly reduced (~73%, p<0.01) RDH12 protein levels.




Figure 5. Proposed pathogenetic mechanism of the *RDH12*: c.[-123C>T];[701G>A] complex allele. Graphical representation of the *RDH12* wild-type allele (*top*) and the *RDH12* complex allele harboring the c.701G>A (p.Arg234His) and the c.-123C>T variants (*bottom*). The 5'UTR variant introduces an upstream start codon into a strong Kozak sequence which can be recognized by ribosomes. Either initiation or active translation of the introduced upstream open reading frame (uORF) results in lower translational efficiency of the primary open reading frame (pORF). As a result, there is a decreased level of RDH12 protein with the arginine-to-histidine amino acid substitution at position 734 (*blue point*).




Figure S1. Schematic overview of constructs used for functional studies. (A) The wild-type (WT) 5'UTRs of the *MERTK*, *PAX6*, and *RDH12* genes were cloned in-frame into a psiCHECK™-2 dual luciferase vector (Promega), containing the *Renilla* and *Firefly* luciferase reporter genes under the regulation of the SV40 and HSV-TK promoters, respectively. (B). Depiction of the overexpression RDH12 construct comprising the 5'UTR and primary open reading frame (pORF) of *RDH12*, for which Myc and FLAG inframe tags were included downstream, respectively. This fragment was cloned into a pcDNA™3.1⁽⁺⁾ (Invitrogen) vector downstream its T7 promoter. For all constructs, 5'UTRs variants were created by site-directed mutagenesis to obtain mutant (MT) constructs with the variants of interest.




Figure S2. Assessment of transcription start site (TSS) confidence by CAGE-seq in retina.

Representation of the proportion of IRD gene isoforms based on the support of their annotated TSS provided by CAGE-seq data derived from adult and fetal retina.




Figure S3. Retina-enriched non-canonical isoforms of the *CRB1* and *RIMS2* genes. The shorter alternative isoforms of (A) *CRB1* (ENST00000681519) and (B) *RIMS2* (ENST00000436393) contain 5'UTRs which are completely distinct to those of their respective canonical isoforms

(ENST00000367400.8 and ENST00000696799.1, respectively). The transcription start sites (supported by CAGE-seq) of each canonical and non-canonical isoform (indicated by arrows) are highlighted in *yellow* and *blue*, respectively. Active retinal transcription is supported by bulk RNA-seq and Nuc-seq derived from human retina. The enrichment in retina of these isoforms is further supported by signatures of open chromatin, H3K4me2, and binding of the retina-specific transcription factor CRX (datasets used are listed in **Table S2**).




Figure S4. Evaluation of 5'UTR capture by the kits mostly used for generating our in-house WES data.

Comparison of the capture performance of the SureSelect Human All Exon V6 and V7 kits (Agilent Technologies) considering *strict* or *padded* designs (*see Methods*).




Figure S5. Pedigrees of families carrying the 11 candidate 5'UTR variants and segregation analysis.

(J) Upon clinical re-evaluation, the sibling of F10 (gray) was found to be affected by an acquired vascular ocular condition instead of an IRD. Abbreviations: WT, wild-type allele; M, mutated allele.

775




Figure S6. Secondary structure prediction for wild-type and mutated 5'UTR sequences. Secondary structure analysis of the 5'UTR sequences (*Ufold* using default parameters) revealed different folding for the **(A)** *ARL3*:c.-88G>A, **(B)** *MERTK*:c.-125G>A, **(C)** *PAX6*:c.-44T>C, **(D)** *RD3*:c.-394G>A variants in comparison to their corresponding wild-type 5'UTRs.




Figure S7. Kozak consensus sequence of all IRD gene isoforms evaluated in this study. The nucleotides within the -1 to -10 positions relative to the main AUG were retrieved for all selected transcripts. Frequency plots corresponding to the Kozak sequences of the (A) retina-enriched (373) and (B) not retina-enriched canonical transcripts (76).

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

Tables <u>Table 2.</u> Summarized overview of the 5'UTR variants that were prioritized as candidates. Abbreviations: AD, autosomal dominant; AR, autosomal recessive; CMGG, Center for Medical Genetics Ghent; GE, Genomics England; LCA, Leber Congenital Amaurosis; MAF, minor allele frequency; TSS, transcription start site; uORF, upstream open reading frame. **Additional files** Additional file 1 - Supplementary Tables. Table S1. Custom diagnostic gene panel comprising all IRD genes listed in either the Retinal disorders panel (v2.195) from Genomics England PanelApp or RetNet. Abbreviations: AD, autosomal dominant; AR, autosomal recessive; HGNC, HUGO Gene Nomenclature Committee. **Table S2.** Publicly available multi-omics datasets derived from human retina used in this study. Table S3. Overview of the IRD sub-cohort from the Rare Disease arm of the 100,000 Genomes Project (Genomics England). **Table S4**. Primer sequences used in this study. Table S5. Overview of selected canonical and non-canonical protein-coding transcripts of IRD genes and their expression in adult human retina. Abbreviations: MANE, Matched Annotation from NCBI and EMBL-EBI; SD, standard deviation; TPM, transcripts per million; TSS, transcription start site. Table S6. Genomic coordinates (GRCh38) of the regions in which variants were searched in this study (5'UTR analysis file). **Table S7**. Overview of the structure of 5'UTRs of the transcripts included in this study.

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

Table S8. Comparison of 5'UTRs of non-canonical transcripts with respect to their corresponding canonical isoforms. **Table S9.** Overview of the performance of commercial exome capture designs on the 5'UTRs screened in this study. **Table S10**. Overview of the performance of commercial exome capture kits mostly used for the generation of our in-house WES data considering strict and padded designs. Table S11. Overview of all 5'UTR variants reported in IRD genes submitted to the ClinVar database. Table S12. Overview of the span of internal ribosomal entry sites (IRES) contained in the 5'UTR of IRD genes. Table S13. Illustration of the designed prioritization strategy applied to a selection of the identified variants. Variants which did not pass all criteria (strikethrough) were not prioritized as candidates (bold). Table \$14. Overview of additional variants reported for patients F5, F8, F11. Abbreviations: ACMG, American College of Medical Genetics and Genomics; MAF, minor allele frequency. Table S15. Overview of the 11 patients carrying the RDH12:c.701G>A (p.Arg234His) variant found in cis with RDH12:c.-123C>T. Abbreviations: ARG: Argentina; CMGG, Center for Medical Genetics Ghent; GE, Genomics England; HU FJD: Hospital Universitario Fundación Jiménez Díaz; IOB: Institute of Molecular and Clinical Ophthalmology Basel; MEH: Moorfields Eye Hospital. Additional file 2 - Dataset S1. Annotation of the 1,450 5'UTRs variants that remained after functional classification and filtering. For each cohort (GE or CMGG) there is one tab per functional category.

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

Declarations Ethics approval and consent to participate The 100,000 Genomes Project Protocol has ethical approval from the HRA Committee East of England – Cambridge South (REC Ref 14/EE/1112). This study was registered with Genomics England within the Hearing and sight domain under Research Registry Projects 465. This study was approved by the ethics committee for Ghent University Hospital (B6702021000312) and performed in accordance with the tenets of the Helsinki Declaration and subsequent reviews. **Consent for publication** Not applicable. We present only de-identified data. Availability of data and materials The data that support the findings of this study are available within the Genomics England (protected) Research Environment but restrictions apply to the availability of these data, as access to the Research Environment is limited to protect the privacy and confidentiality of participants. Likewise, healthcare and genomic data derived from individuals included in the Center for Medical Genetics Ghent (CMGG) cohort are not publicly available to comply with the consent given by those participants. De-identified data as well as analysis scripts are available from the authors upon reasonable request. Extended data generated in this study are available in the supplementary materials. **Competing interests** The authors declare that they have no competing interests. **Funding** This work was supported by the Ghent University Special Research Fund (BOF20/GOA/023; BOF/STA/201909/016) (EDB, BPL, FCP); H2020 Marie Sklodowska-Curie Innovative Training

Networks (ITN) StarT (grant No. 813490) (ADR, EDB, FC); Ghent University Hospital under the

858

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

877

878

879

880

NucleUZ Grant (EDB, FC); Foundation Fighting Blindness (TA-GT-0621-0810-UGENT) (FCP); EJPRD19-234 Solve-RET (EDB); Fundación Alfonso Martin Escudero (MDPV); Instituto de Salud Carlos III (ISCIII) of the Spanish Ministry of Health (CA; FIS: PI22/00321); University Chair UAM-IIS-FJD of Genomic Medicine (CA). GA is funded by a Fight For Sight UK Early Career Investigator Award (5045/46), National Institute of Health Research Biomedical Research Centre (NIHR-BRC) at Moorfields Eye Hospital and UCL Institute of Ophthalmology and NIHR-BRC at Great Ormond Street Hospital Institute for Child Health. **Authors' contributions** ADR: Conception and project design, acquisition of data, analysis and interpretation of data, drafting and revising the manuscript. MDPV: Acquisition of data, analysis and interpretation of data, drafting and revising the manuscript. MB: Acquisition of data, analysis and interpretation of data, revising the manuscript. FVB: Acquisition of data, revising the manuscript. MDV: Acquisition of data, revising the manuscript. MVH: Acquisition of data, revising the manuscript. MDB: Acquisition of data, revising the manuscript. SVS: Acquisition of data, revising the manuscript. MBW: Acquisition of data, revising the manuscript. JE: Acquisition of data, revising the manuscript. GER: Acquisition of data, revising the manuscript. CR: Acquisition of data, revising the manuscript. AW: Acquisition of data, revising the manuscript. GA: Acquisition of data, revising the manuscript.

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

900

901

902

CA: Acquisition of data, revising the manuscript. JDZ: Acquisition of data, revising the manuscript. BL: Acquisition of data, revising the manuscript. EDB: Project supervision, acquisition of data, revising the manuscript. FC: Conception and project supervision, acquisition of data, analysis and interpretation of data, revising the manuscript. **Acknowledgements** This research was made possible through access to the data and findings generated by the 100,000 Genomes Project. The 100,000 Genomes Project is managed by Genomics England Limited (a wholly owned company of the Department of Health and Social Care). The 100,000 Genomes Project is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded research infrastructure. The 100,000 Genomes Project uses data provided by patients and collected by the National Health Service as part of their care and support. We thank Olga Zurita for their excellent technical assistance. We are grateful to Dr. Jacqueline Cook and Dr. Savita Madhusudhan for their clinical input.

References

- Jackson RJ, Hellen CUT, Pestova T V. THE MECHANISM OF EUKARYOTIC TRANSLATION
 INITIATION AND PRINCIPLES OF ITS REGULATION. doi:10.1038/nrm2838
- Araujo PR, Yoon K, Ko D, et al. Before It Gets Started: Regulating Translation at the 5' UTR.
 Comp Funct Genomics. 2012;2012. doi:10.1155/2012/475731
- 908 3. Kozak M. Influences of mRNA secondary structure on initiation by eukaryotic ribosomes. *Proc* 909 *Natl Acad Sci U S A*. 1986;83(9):2850-2854. doi:10.1073/PNAS.83.9.2850
- 910 4. Sonenberg N, Hinnebusch AG. Regulation of Translation Initiation in Eukaryotes: Mechanisms and Biological Targets. *Cell.* 2009;136(4):731. doi:10.1016/J.CELL.2009.01.042
- 5. Calvo SE, Pagliarini DJ, Mootha VK. Upstream open reading frames cause widespread
 reduction of protein expression and are polymorphic among humans. *Proc Natl Acad Sci U S* A. 2009;106(18):7507. doi:10.1073/PNAS.0810916106
- Leppek K, Das R, Barna M. Functional 5' UTR mRNA structures in eukaryotic translation
 regulation and how to find them HHS Public Access. *Nat Rev Mol Cell Biol*. 2018;19(3):158 174. doi:10.1038/nrm.2017.103
- 918 7. Bugaut A, Balasubramanian S. 5'-UTR RNA G-quadruplexes: translation regulation and targeting. doi:10.1093/nar/gks068
- 920 8. Steri M, Idda ML, Whalen MB, Orrù V. Genetic Variants in mRNA Untranslated Regions. *Wiley Interdiscip Rev RNA*. 2018;9(4):e1474. doi:10.1002/WRNA.1474
- 922 9. Barbosa C, Peixeiro I, Romão L. Gene Expression Regulation by Upstream Open Reading
 923 Frames and Human Disease. *PLOS Genet*. 2013;9(8):e1003529.
 924 doi:10.1371/JOURNAL.PGEN.1003529
- 925 10. Soukarieh O, Meguerditchian C, Proust C, et al. Common and Rare 5'UTR Variants Altering
 926 Upstream Open Reading Frames in Cardiovascular Genomics. Front Cardiovasc Med.
 927 2022;9:542. doi:10.3389/FCVM.2022.841032/BIBTEX
- 928 11. Whiffin N, Karczewski KJ, Zhang X, et al. Characterising the loss-of-function impact of 5' 929 untranslated region variants in 15,708 individuals. *Nat Commun 2020 111*. 2020;11(1):1-12. 930 doi:10.1038/s41467-019-10717-9
- 931 12. Smedley D, Smith KR, Martin A, et al. 100,000 Genomes Pilot on Rare-Disease Diagnosis in
 932 Health Care Preliminary Report. N Engl J Med. 2021;385(20):1868-1880.
 933 doi:10.1056/nejmoa2035790
- 934 13. Wright CF, FitzPatrick DR, Firth H V. Paediatric genomics: diagnosing rare disease in children. 935 Nat Rev Genet 2018 195. 2018;19(5):253-268. doi:10.1038/nrg.2017.116
- 936 14. Fernández-Marmiesse A, Gouveia S, Couce ML. NGS Technologies as a Turning Point in Rare 937 Disease Research, Diagnosis and Treatment. *Curr Med Chem*. 2018;25(3):404. 938 doi:10.2174/0929867324666170718101946
- 939 15. Carss K, Arno G, Erwood M, et al. Comprehensive Rare Variant Analysis via Whole-Genome 940 Sequencing to Determine the Molecular Pathology of Inherited Retinal Disease. *Am J Hum* 941 *Genet*. 2017;100(1):75-90. doi:10.1016/J.AJHG.2016.12.003
- 942 16. Retterer K, Juusola J, Cho MT, et al. Clinical application of whole-exome sequencing across clinical indications. *Genet Med 2016 187*. 2015;18(7):696-704. doi:10.1038/gim.2015.148

- 944 17. Lionel AC, Costain G, Monfared N, et al. Improved diagnostic yield compared with targeted 945 gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic 946 test. *Genet Med.* 2018;20(4):435-443. doi:10.1038/GIM.2017.119
- 947 18. Dai P, Honda A, Ewans L, et al. Recommendations for next generation sequencing data 948 reanalysis of unsolved cases with suspected Mendelian disorders: A systematic review and 949 meta-analysis. *Genet Med.* 2022;24(8):1618-1629. doi:10.1016/J.GIM.2022.04.021
- 950 19. Wright CF, Quaife NM, Ramos-Hernández L, et al. Non-coding region variants upstream of
 951 MEF2C cause severe developmental disorder through three distinct loss-of-function
 952 mechanisms. Am J Hum Genet. 2021;108(6):1083. doi:10.1016/J.AJHG.2021.04.025
- Zhang X, Wakeling M, Ware J, Whiffin N. Annotating high-impact 5'untranslated region
 variants with the UTRannotator. *Bioinformatics*. 2021;37(8):1171-1173.
 doi:10.1093/BIOINFORMATICS/BTAA783
- 956 21. Wang J, Gribskov M. IRESpy: An XGBoost model for prediction of internal ribosome entry sites. *BMC Bioinformatics*. 2019;20(1):1-15. doi:10.1186/S12859-019-2999-7/FIGURES/10
- 958 22. Chatterjee S, Pal JK. Role of 5'- and 3'-untranslated regions of mRNAs in human diseases. *Biol Cell*. 2009;101(5):251-262. doi:10.1042/BC20080104
- Jaganathan K, Kyriazopoulou Panagiotopoulou S, McRae JF, et al. Predicting Splicing from
 Primary Sequence with Deep Learning. *Cell*. 2019;176(3):535-548.e24.
 doi:10.1016/J.CELL.2018.12.015
- Zhao J, Wu J, Xu T, Yang Q, He J, Song X. IRESfinder: Identifying RNA internal ribosome entry
 site in eukaryotic cell using framed k-mer features. *J Genet Genomics*. 2018;45(7):403-406.
 doi:10.1016/J.JGG.2018.07.006
- 25. Lim Y, Arora S, Schuster SL, et al. Multiplexed functional genomic analysis of 5' untranslated
 region mutations across the spectrum of prostate cancer. *Nat Commun 2021 121*.
 2021;12(1):1-18. doi:10.1038/s41467-021-24445-6
- 969 26. Filatova A, Reveguk I, Piatkova M, et al. Annotation of uORFs in the OMIM genes allows to
 970 reveal pathogenic variants in 5'UTRs. *Nucleic Acids Res.* 2023;51(3):1229-1244.
 971 doi:10.1093/nar/gkac1247
- 972 27. Ellingford JM, Ahn JW, Bagnall RD, et al. Recommendations for clinical interpretation of variants found in non-coding regions of the genome. *Genome Med*. 2022;14(1):1-19. doi:10.1186/S13073-022-01073-3/FIGURES/3
- 975 28. Pontikos N, Arno G, Jurkute N, et al. Genetic Basis of Inherited Retinal Disease in a Molecularly 976 Characterized Cohort of More Than 3000 Families from the United Kingdom. Published online 977 2020. doi:10.1016/j.ophtha.2020.04.008
- Page 29. Ratnapriya R, Swaroop A. Genetic architecture of retinal and macular degenerative diseases:
 the promise and challenges of next-generation sequencing. *Genome Med.* 2013;5(10).
 doi:10.1186/GM488
- 981 30. O'sullivan J, Mullaney BG, Bhaskar SS, et al. A paradigm shift in the delivery of services for diagnosis of inherited retinal disease. doi:10.1136/jmedgenet-2012-100847
- 983 31. Dockery A, Whelan L, Humphries P, Farrar GJ, Malerba G. Next-Generation Sequencing
 984 Applications for Inherited Retinal Diseases. Published online 2021. doi:10.3390/ijms22115684
- 985 32. Berger W, Kloeckener-Gruissem B, Neidhardt J. The molecular basis of human retinal and vitreoretinal diseases. *Prog Retin Eye Res.* 2010;29(5):335-375.

987 doi:10.1016/J.PRETEYERES.2010.03.004 988 33. Hanany M, Rivolta C, Sharon D. Worldwide carrier frequency and genetic prevalence of 989 autosomal recessive inherited retinal diseases. Proc Natl Acad Sci U S A. 2020;117(5):2710-990 2716. doi:10.1073/PNAS.1913179117 991 34. RetNet - Retinal Information Network. Accessed April 6, 2023. 992 https://web.sph.uth.edu/RetNet/ 993 35. Tatour Y, Ben-Yosef T. Syndromic Inherited Retinal Diseases: Genetic, Clinical and Diagnostic 994 Aspects. Diagnostics (Basel, Switzerland). 2020;10(10). doi:10.3390/DIAGNOSTICS10100779 995 36. Ellingford JM, Hufnagel RB, Arno G. Phenotype and Genotype Correlations in Inherited Retinal 996 Diseases: Population-Guided Variant Interpretation, Variable Expressivity and Incomplete 997 Penetrance. Genes (Basel). 2020;11(11):1-4. doi:10.3390/GENES11111274 998 37. Sharon D, Ben-Yosef T, Goldenberg-Cohen N, et al. A nationwide genetic analysis of inherited 999 retinal diseases in Israel as assessed by the Israeli inherited retinal disease consortium (IIRDC). 1000 Hum Mutat. 2020;41(1):140-149. doi:10.1002/HUMU.23903 1001 38. Perea-Romero I, Gordo G, Iancu IF, et al. Genetic landscape of 6089 inherited retinal 1002 dystrophies affected cases in Spain and their therapeutic and extended epidemiological 1003 implications. Sci Rep. 2021;11(1). doi:10.1038/S41598-021-81093-Y 1004 39. Fadaie Z, Whelan L, Ben-Yosef T, et al. Whole genome sequencing and in vitro splice assays 1005 reveal genetic causes for inherited retinal diseases. NPJ genomic Med. 2021;6(1). 1006 doi:10.1038/S41525-021-00261-1 1007 40. Lenassi E, Clayton-Smith J, Douzgou S, et al. Clinical utility of genetic testing in 201 preschool 1008 children with inherited eye disorders. Genet Med. 2020;22(4):745-751. doi:10.1038/S41436-1009 019-0722-8 1010 41. Lam BL, Leroy BP, Black G, Ong T, Yoon D, Trzupek K. Genetic testing and diagnosis of 1011 inherited retinal diseases. Orphanet J Rare Dis. 2021;16(1):1-9. doi:10.1186/S13023-021-1012 02145-0/TABLES/2 1013 42. Liquori A, Vaché C, Baux D, et al. Whole USH2A Gene Sequencing Identifies Several New Deep 1014 Intronic Mutations. Hum Mutat. 2016;37(2):184-193. doi:10.1002/HUMU.22926 1015 43. Holtan JP, Selmer KK, Heimdal KR, Bragadóttir R. Inherited retinal disease in Norway - a 1016 characterization of current clinical and genetic knowledge. Acta Ophthalmol. 2020;98(3):286-1017 295. doi:10.1111/AOS.14218 1018 44. Reurink J, Weisschuh N, Garanto A, et al. Whole genome sequencing for USH2A-associated 1019 disease reveals several pathogenic deep-intronic variants that are amenable to splice correction. HGG Adv. 2023;4(2). doi:10.1016/J.XHGG.2023.100181 1020 1021 45. Bauwens M, Garanto A, Sangermano R, et al. ABCA4-associated disease as a model for missing 1022 heritability in autosomal recessive disorders: novel noncoding splice, cis-regulatory, 1023 structural, and recurrent hypomorphic variants. Genet Med. 2019;21(8):1761-1771. doi:10.1038/S41436-018-0420-Y 1024 1025 46. Sangermano R, Garanto A, Khan M, et al. Deep-intronic ABCA4 variants explain missing 1026 heritability in Stargardt disease and allow correction of splice defects by antisense 1027 oligonucleotides. Genet Med. 2019;21(8):1751-1760. doi:10.1038/S41436-018-0414-9 47. 1028 Khan M, Cornelis SS, Pozo-Valero M Del, et al. Resolving the dark matter of ABCA4 for 1054

Stargardt disease probands through integrated genomics and transcriptomics. Genet Med.

1030 2020;22(7):1235-1246. doi:10.1038/S41436-020-0787-4 1031 48. Daich Varela M, Bellingham J, Motta F, et al. Multidisciplinary team directed analysis of whole 1032 genome sequencing reveals pathogenic non-coding variants in molecularly undiagnosed 1033 inherited retinal dystrophies. Hum Mol Genet. 2023;32(4):595-607. 1034 doi:10.1093/HMG/DDAC227 1035 49. Qian X, Wang J, Wang M, et al. Identification of Deep-Intronic Splice Mutations in a Large 1036 Cohort of Patients With Inherited Retinal Diseases. Front Genet. 2021;12:276. 1037 doi:10.3389/FGENE.2021.647400/BIBTEX 1038 50. Weisschuh N, Sturm M, Baumann B, et al. Deep-intronic variants in CNGB3 cause 1039 achromatopsia by pseudoexon activation HHS Public Access. Hum Mutat. 2020;41(1):255-264. 1040 doi:10.1002/humu.23920 51. 1041 Jamshidi F, Place EM, Mehrotra S, et al. Contribution of noncoding pathogenic variants to 1042 RPGRIP1-mediated inherited retinal degeneration. Genet Med. 2019;21(3):694-704. 1043 doi:10.1038/S41436-018-0104-7 52. 1044 Cherry TJ, Yang MG, Harmin DA, et al. Mapping the cis-regulatory architecture of the human 1045 retina reveals noncoding genetic variation in disease. Proc Natl Acad Sci U S A. 1046 2020;117(16):9001-9012. doi:10.1073/PNAS.1922501117/-/DCSUPPLEMENTAL 1047 53. Coppieters F, Todeschini AL, Fujimaki T, et al. Hidden Genetic Variation in LCA9-Associated 1048 Congenital Blindness Explained by 5'UTR Mutations and Copy-Number Variations of NMNAT1. 1049 Hum Mutat. 2015;36(12):1188. doi:10.1002/HUMU.22899 1050 54. Ruberto FP, Balzano S, Namburi P, et al. Heterozygous deletions of noncoding parts of the 1051 PRPF31 gene cause retinitis pigmentosa via reduced gene expression. Mol Vis. 2021;27:107. 1052 Accessed April 11, 2023. /pmc/articles/PMC8056469/ 1053 55. Van de Sompele S, Small KW, Cicekdal MB, et al. Multi-omics approach dissects cis-regulatory 1054 mechanisms underlying North Carolina macular dystrophy, a retinal enhanceropathy. Am J 1055 Hum Genet. 2022;109(11):2029-2048. doi:10.1016/J.AJHG.2022.09.013 1056 56. Small KW, DeLuca AP, Whitmore SS, et al. North Carolina Macular Dystrophy is caused by 1057 dysregulation of the retinaltranscription factor PRDM13. Ophthalmology. 2016;123(1):9. 1058 doi:10.1016/J.OPHTHA.2015.10.006 1059 57. Filatova AY, Vasilyeva TA, Marakhonov A V., et al. Upstream ORF frameshift variants in the 1060 PAX6 5'UTR cause congenital aniridia. Hum Mutat. 2021;42(8):1053-1065. doi:10.1002/HUMU.24248 1061 1062 58. Zuercher J, Neidhardt J, Magyar I, et al. Alterations of the 5'Untranslated Region of SLC16A12 1063 Lead to Age-Related Cataract. Invest Ophthalmol Vis Sci. 2010;51(7):3354. 1064 doi:10.1167/IOVS.10-5193 1065 59. Zhang W, Kassels AC, Barrington A, et al. Macular corneal dystrophy with isolated peripheral 1066 Descemet membrane deposits. Am J Ophthalmol Case Reports. 2019;16. 1067 doi:10.1016/J.AJOC.2019.100571 60. 1068 Ratnapriya R, Sosina OA, Starostik MR, et al. Retinal transcriptome and eQTL analyses identify 1069 genes associated with age-related macular degeneration. Nat Genet. 2019;51(4):606-610. 1070 doi:10.1038/S41588-019-0351-9 1071 61. Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seg quantification.

Nat Biotechnol. 2016;34(5):525-527. doi:10.1038/NBT.3519

1073	62.	Morales J, Pujar S, Loveland JE, et al. A joint NCBI and EMBL-EBI transcript set for clinical
1074		genomics and research. Nature. 2022;604(7905). doi:10.1038/S41586-022-04558-8

- 1075 63. Martin AR, Williams E, Foulger RE, et al. PanelApp crowdsources expert knowledge to establish consensus diagnostic gene panels. *Nat Genet*. 2019;51(11):1560-1565. doi:10.1038/S41588-019-0528-2
- 1078 64. Forrest ARR, Kawaji H, Rehli M, et al. A promoter-level mammalian expression atlas. *Nature*. 2014;507(7493):462-470. doi:10.1038/NATURE13182
- 1080 65. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features.

 1081 Bioinforma Appl NOTE. 2010;26(6):841-842. doi:10.1093/bioinformatics/btq033
- Landrum MJ, Lee JM, Benson M, et al. ClinVar: public archive of interpretations of clinically relevant variants. *Nucleic Acids Res.* 2016;44(D1):D862-D868. doi:10.1093/NAR/GKV1222
- 1084 67. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. 2009;25(14):1754-1760. doi:10.1093/bioinformatics/btp324
- 1086 68. McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce framework 1087 for analyzing next-generation DNA sequencing data. *Genome Res*. 2010;20(9):1297-1303. 1088 doi:10.1101/GR.107524.110
- 1089 69. Danecek P, Bonfield JK, Liddle J, et al. Twelve years of SAMtools and BCFtools. *Gigascience*. 2021;10(2). doi:10.1093/GIGASCIENCE/GIAB008
- 1091 70. McLaren W, Gil L, Hunt SE, et al. The Ensembl Variant Effect Predictor. *Genome Biol.* 2016;17(1). doi:10.1186/S13059-016-0974-4
- 71. Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature*. 2020;581(7809):434-443. doi:10.1038/S41586-020-1095 2308-7
- 1096 72. Jian X, Boerwinkle E, Liu X. In silico prediction of splice-altering single nucleotide variants in the human genome. *Nucleic Acids Res.* 2014;42(22):13534-13544. doi:10.1093/NAR/GKU1206
- Yeo G, Burge CB. Maximum Entropy Modeling of Short Sequence Motifs with Applications to
 RNA Splicing Signals. https://home.liebertpub.com/cmb. 2004;11(2-3):377-394.
 doi:10.1089/1066527041410418
- 1101 74. Frazer J, Notin P, Dias M, et al. Disease variant prediction with deep generative models of evolutionary data. *Nat 2021 5997883*. 2021;599(7883):91-95. doi:10.1038/s41586-021-04043-1103 8
- 1104 75. Kircher M, Witten DM, Jain P, O'roak BJ, Cooper GM, Shendure J. A general framework for
 1105 estimating the relative pathogenicity of human genetic variants. *Nat Genet*. 2014;46(3):310 1106 315. doi:10.1038/NG.2892
- 76. Zerbino DR, Wilder SP, Johnson N, Juettemann T, Flicek PR. The ensembl regulatory build.
 1108 *Genome Biol.* 2015;16(1):56-56. doi:10.1186/S13059-015-0621-5
- 77. Kozak M. The scanning model for translation: an update. *J Cell Biol*. 1989;108(2):229-241.
 1110 doi:10.1083/JCB.108.2.229
- 78. McClements ME, Butt A, Piotter E, Peddle CF, Maclaren RE. An analysis of the Kozak
 1112 consensus in retinal genes and its relevance to gene therapy. *Mol Vis*. 2021;27:233. Accessed
 1113 March 15, 2023. /pmc/articles/PMC8116250/
- 1114 79. Crooks GE, Hon G, Chandonia JM, Brenner SE. WebLogo: a sequence logo generator. *Genome*

1115 Res. 2004;14(6):1188-1190. doi:10.1101/GR.849004 1116 80. Sample PJ, Wang B, Reid DW, et al. Human 5' UTR design and variant effect prediction from a massively parallel translation assay. Nat Biotechnol 2019 377. 2019;37(7):803-809. 1117 1118 doi:10.1038/s41587-019-0164-5 1119 81. Murat P, Marsico G, Herdy B, Ghanbarian A, Portella G, Balasubramanian S. RNA G-1120 quadruplexes at upstream open reading frames cause DHX36- and DHX9-dependent 1121 translation of human mRNAs. Genome Biol. 2018;19(1):1-24. doi:10.1186/S13059-018-1602-2/FIGURES/6 1122 1123 82. Li H. Tabix: fast retrieval of sequence features from generic TAB-delimited files. 1124 Bioinformatics. 2011;27(5):718. doi:10.1093/BIOINFORMATICS/BTQ671 1125 83. Fu L, Cao Y, Wu J, Peng Q, Nie Q, Xie X. UFold: fast and accurate RNA secondary structure 1126 prediction with deep learning. Nucleic Acids Res. 2022;50(3):e14-e14. 1127 doi:10.1093/NAR/GKAB1074 1128 84. Chen CC, Chan YM. REDfold: accurate RNA secondary structure prediction using residual 1129 encoder-decoder network. BMC Bioinformatics. 2023;24(1):122. doi:10.1186/S12859-023-1130 05238-8/FIGURES/3 1131 85. Sato K, Akiyama M, Sakakibara Y. RNA secondary structure prediction using deep learning 1132 with thermodynamic integration. Nat Commun 2021 121. 2021;12(1):1-9. 1133 doi:10.1038/s41467-021-21194-4 1134 86. Yang TH, Wang CY, Tsai HC, Liu CT. Human IRES Atlas: an integrative platform for studying 1135 IRES-driven translational regulation in humans. Database. 2021;2021:1-16. 1136 doi:10.1093/DATABASE/BAAB025 87. Bates D, Mächler M, Bolker BM, Walker SC. Fitting Linear Mixed-Effects Models Using Ime4. J 1137 Stat Softw. 2015;67(1):1-48. doi:10.18637/JSS.V067.I01 1138 1139 88. Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J. qBase relative 1140 quantification framework and software for management and automated analysis of real-time 1141 quantitative PCR data. Published online 2007. doi:10.1186/gb-2007-8-2-r19 1142 Dryja TP, McGee TL, Berson EL, et al. Night blindness and abnormal cone electroretinogram 89. 1143 ON responses in patients with mutations in the GRM6 gene encoding mGluR6. Proc Natl Acad 1144 Sci U S A. 2005;102(13). doi:10.1073/pnas.0501233102 90. De Zaeytijd J, Van Cauwenbergh C, De Bruyne M, et al. ISOLATED MACULOPATHY AND 1145 1146 MODERATE ROD-CONE DYSTROPHY REPRESENT THE MILDER END OF THE RDH12-RELATED 1147 RETINAL DYSTROPHY SPECTRUM. Retina. 2021;41(6):1346-1355. 1148 doi:10.1097/IAE.0000000000003028 1149 91. Tiering (Rare Disease) - Genomics England Research Environment - Genomics England 1150 Confluence. Accessed April 14, 2023. 1151 https://cnfl.extge.co.uk/pages/viewpage.action?pageId=113194832 1152 92. Schmitz-Abe K, Li Q, Rosen SM, et al. Unique bioinformatic approach and comprehensive 1153 reanalysis improve diagnostic yield of clinical exomes. Eur J Hum Genet 2019 279. 2019;27(9):1398-1405. doi:10.1038/s41431-019-0401-x 1154 1155 93. Wenger AM, Guturu H, Bernstein JA, Bejerano G. Systematic reanalysis of clinical exome data 1156 yields additional diagnoses: implications for providers. Genet Med. 2017;19(2):209-214.

1157

doi:10.1038/GIM.2016.88

1158 94. de Bruijn SE, Rodenburg K, Corominas J, et al. Optical genome mapping and revisiting short-1159 read genome sequencing data reveal previously overlooked structural variants disrupting 1160 retinal disease-associated genes. Genet Med. 2023;25(3). doi:10.1016/J.GIM.2022.11.013 95. 1161 Del Pozo-Valero M, Martin-Merida I, Jimenez-Rolando B, et al. Expanded Phenotypic 1162 Spectrum of Retinopathies Associated with Autosomal Recessive and Dominant Mutations in 1163 PROM1. Am J Ophthalmol. 2019;207:204-214. doi:10.1016/J.AJO.2019.05.014 1164 96. Moreno-Leon L, West EL, O'Hara-Wright M, et al. RPGR isoform imbalance causes ciliary 1165 defects due to exon ORF15 mutations in X-linked retinitis pigmentosa (XLRP). Hum Mol Genet. 1166 2021;29(22):3706-3716. doi:10.1093/HMG/DDAA269 1167 97. Vig A, Poulter JA, Ottaviani D, et al. DYNC2H1 hypomorphic or retina-predominant variants 1168 cause nonsyndromic retinal degeneration. Genet Med. 2020;22(12):2041-2051. 1169 doi:10.1038/S41436-020-0915-1 98. 1170 Riazuddin SA, Igbal M, Wang Y, et al. A splice-site mutation in a retina-specific exon of BBS8 1171 causes nonsyndromic retinitis pigmentosa. Am J Hum Genet. 2010;86(5):805-812. 1172 doi:10.1016/J.AJHG.2010.04.001 1173 99. Mairot K, Smirnov V, Bocquet B, et al. CRB1-Related Retinal Dystrophies in a Cohort of 50 1174 Patients: A Reappraisal in the Light of Specific Müller Cell and Photoreceptor CRB1 Isoforms. 1175 Int J Mol Sci. 2021;22(23):12642. doi:10.3390/IJMS222312642 1176 Weber R, Ghoshdastider U, Spies D, et al. Monitoring the 5'UTR landscape reveals isoform 1177 switches to drive translational efficiencies in cancer. Oncogene. 2023;42(9):638-650. 1178 doi:10.1038/S41388-022-02578-2 1179 101. Ray TA, Cochran K, Kozlowski C, et al. Comprehensive identification of mRNA isoforms reveals 1180 the diversity of neural cell-surface molecules with roles in retinal development and disease. 1181 Nat Commun. 2020;11(1). doi:10.1038/S41467-020-17009-7 1182 102. Yu M, Baehr W, Lei B, et al. A Novel ARL3 Gene Mutation Associated With Autosomal 1183 Dominant Retinal Degeneration. Published online 2021. doi:10.3389/fcell.2021.720782 1184 103. Wang J, Wang Y, Li S, et al. Clinical and Genetic Analysis of RDH12-Associated Retinopathy in 1185 27 Chinese Families: A Hypomorphic Allele Leads to Cone-Rod Dystrophy. Published online 1186 2022. doi:10.1167/iovs.63.9.24 1187 104. Ba-Abbad R, Arno G, Robson AG, et al. Macula-predominant retinopathy associated with 1188 biallelic variants in RDH12. Ophthalmic Genet. 2020;41(6):612-615. doi:10.1080/13816810.2020.1802763 1189

1192 Hum Mol Genet. 2005;14(24):3865-3875. doi:10.1093/HMG/DDI411